Longitudinal quality of life while on chemotherapy
nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy. Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot…
nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy. Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot…
Measuring Quality Is Complicated Patt D, Page R. J Oncol Pract. 2017 Dec 6:JOP2017027789. doi: 10.1200/JOP.2017.027789. [Epub ahead of print] No abstract available. PMID: 29211577
Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors Daly B, Bach PB, Page RD. JAMA Oncol. 2017 Dec 21. doi: 10.1001/jamaoncol.2017.4473. [Epub ahead of…
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. BACKGROUND:The…
The VeriStrat 1 (VS) test is intended to help guide treatment decisions for patients with advanced non-small-cell lung cancer (NSCLC) without an EGFR-sensitizing mutation, classifying…
RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in…
Stomatitis is a class effect associated with the inhibition of mTOR and is associated with everolimus therapy for breast cancer. Topical steroids might reduce stomatitis…
Stomatitis is a class effect associated with the inhibition of mTOR and is associated with everolimus therapy for breast cancer. Topical steroids might reduce stomatitis…
https://www.ncbi.nlm.nih.gov/pubmed/28282276
This phase II, open-label study was designed to evaluate the response rate to the polo-like kinase 1 (Plk-1) inhibitor BI 2536 in patients with sensitive-relapsed…